Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | PNMT | P11086 | 3/20 | 0.40 |
| ▸ | MAOB | P27338 | 3/20 | 0.39 |
| ▸ | DPP4 | P27487 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL43013 | 0.80 | IDO1 (0.61) | IDO1PNMTMAOBDPP4ALDH1A1 | |
| SCHEMBL9608984 | 0.79 | GABRA1 (0.41) | IDO1MAOBALDH1A1POLB | |
| Methane SCHEMBL27580279 | 0.78 | IDO1 (0.59) | IDO1PNMTMAOBDPP4ALDH1A1 | |
| Hydrochloric Acid SCHEMBL6169962 | 0.78 | IDO1 (0.62) | IDO1PNMTMAOBDPP4ALDH1A1 | |
| SCHEMBL26748088 | 0.77 | IDO1 (0.42) | IDO1PNMTMAOBDPP4ALDH1A1 | |
| SCHEMBL2095080 | 0.77 | IDO1 (0.42) | IDO1PNMTMAOBDPP4ALDH1A1 | |
| SCHEMBL7539869 | 0.77 | IDO1 (0.42) | IDO1PNMTMAOBDPP4ALDH1A1 | |
| Ethane SCHEMBL27580262 | 0.77 | IDO1 (0.57) | IDO1PNMTMAOBALDH1A1POLB | |
| SCHEMBL8404393 | 0.75 | PNMT (0.48) | IDO1PNMTMAOBDPP4TAAR1 | |
| SCHEMBL5517287 | 0.75 | ALDH1A1 (0.40) | IDO1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556373-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | Pfizer Products Inc. (US) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004035566-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2004-04-29 | — | — | WO | disclosed |
| US-20040077650-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077650-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | IDO1 2549/4885PNMT 603/4885MAOB 1529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.